Background: The xanthine oxidoreductase (XOR) was one of a biomarker reflected oxidant stress. Method and Result: The plasma levels of XOR activity were measured in 57 AHF patients before starting treatment (day 1), 3 (day 3) and 14 (day 14) days after admission. The median plasma levels of XOR activity on admission was 158.0 pmol⋅h−1⋅mL−1 [interquartile range, 32.3–401.0 pmol⋅h−1⋅mL−1], those at day 3 was 17.3 pmol⋅h−1⋅mL−1 [8.7–69.9 pmol⋅h−1⋅mL−1] and those at day 14 was 30.5 pmol⋅h−1⋅mL−1 [7.9–83.6 pmol⋅h−1⋅mL−1]. XOR decreased rapidly and significantly from day 1 to day 3, whereas XOR did not decrease after day 3 (ANOVA, P < .001). Conclusion: The plasma levels of XOR activity decreased with the treatment of AHF. This is the first report regarding the time dependent change of XOR in AHF.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect